The novel SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to pose a threat to global public health and has now claimed the lives of more than 3.1 million people worldwide. The large prospective observational study of more than 627,000 individuals found that self-reported infection rates among participants who received either vaccine were significantly lower than among unvaccinated controls. Researchers in the UK and United States have demonstrated the efficacy of one dose of either the Pfizer-BioNTech or Oxford-AstraZeneca vaccine against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a real-world community setting in the UK. As reported in The Lancet: Infectious Diseases, documented infection rates following a single dose of the Pfizer-BioNTech (BNT162b2) vaccine were 58% lower after 12 to 20 days, 69% lower after 21 to 44 days, and 72% lower after 45 to 59 days, compared with unvaccinated controls.
Following one dose of the Oxford-AstraZeneca (ChAdOx1) vaccine, documented infection rates were 39% lower after 12 to 20 days and 60% lower after 21 to 44 days than among unvaccinated controls. Furthermore, reported side-effects following vaccination were moderate in frequency, minor in severity, and of short duration, reports Cristina Menni from King’s College London and colleagues. In the UK, the rollout of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines began on the 8th of December 2020 and the 4th of January 2021, respectively. Based on advice from the Joint Committee on Vaccination and Immunization, the UK Government decided in late December 2020 to delay the administration of second doses. Phase 3 trials have reported efficacy of 52% twelve days following a first dose of the BNT162b2 vaccine and 95% following administration of a second dose 3 to 4 weeks later.
However, a reanalysis of the effectiveness data reported for BNT162b2 in reducing infection, severe disease, hospitalization, and death across the whole of Israel revealed an efficacy of 90% two weeks following just the one dose. A clinical trial of the ChAdOx1 vaccine also reported efficacy against symptomatic COVID-19 of 76% just 22 days following one dose. However, surveillance within the general UK population is needed at this stage of vaccination rollout to assess the safety and effectiveness of these vaccines in the real-time community setting, says Menni and colleagues. The team investigated self-reported adverse effects among 627,383 individuals (aged 16 to 99 years) who received one or two doses of the BNT162b2 vaccine or one dose of the ChAdOx1 vaccines between December 8th, 2020 and March 10th, 2021. Participants self-reported side effects in real-time via the COVID Symptom Study app.
The researchers also compared infection rates among a subset of 103,622 vaccinated individuals who subsequently logged at least one PCR or lateral flow test with rates among 464,356 unvaccinated app users who also logged these test results. Of the 627,383 vaccinated individuals, 282,103 received one dose of BNT162b2, of whom a further 28,207 received a second dose, and 345,280 received one dose of ChAdOx1. The most commonly reported systemic side-effects following vaccination were fatigue and headache, which lasted for a mean of 1·01 days. The most commonly reported local side effects were tenderness and pain at the injection site, which lasted a mean of 1·02 days. A significantly higher proportion of the individuals who received one dose of ChAdOx1 reported systemic side effects, compared with those who received one dose of BNT162b2, at 33.7% versus 13·5%. By contrast, local side effects were less frequently reported after one dose of ChAdOx1 than after one dose of BNT162b2, at 58·7% versus 71·9%
Systemic side effects were 1·6 times more common after one dose of ChAdOx1 and 2·9 times more common after one dose of BNT162b2 among individuals with previous SARS-CoV-2 infection than among those without previous infection. Local effects were similarly more common among individuals with previous infection than among those without (1·4 times more common after one dose of ChAdOx1 and 1·2 times more common after one dose of BNT162b2). The team observed significant reductions in infection risk starting from day 12 following one vaccine dose, reaching 60% for ChAdOx1 and 69% for BNT162b2 after 21 to 44 days and 72% for BNT162b2 after 45 to 59 days. The researchers say that although the observational nature of these data do not directly reflect effectiveness, the observed decrease in infection over time following one vaccine dose supports the UK Government’s decision to delay the timing of a second dose to 12 weeks to maximize the number of people who receive at least one dose.
Another team of researchers probed the effects of COVID vaccination across gender and age groups. In the current study, the scientists have explored the dynamics of IgG-specific anti-SARS-CoV-2 antibody response after the first and second doses of Pfizer-BioNTech mRNA-based COVID-19 vaccine BNT162b2. They have also investigated whether age, sex, and vaccine-related side-effects can influence the vaccine efficacy. The study was conducted on 118 healthy volunteers (age range: 21 – 68 years) who received two doses of the BNT162b2 vaccine. The immune responses of the volunteers were examined up to 6 weeks following the second vaccine dose. Specifically, the post-vaccination time points for monitoring immune response were three weeks after the first dose, just before the second dose, one week after the second dose, and six weeks after the second dose. The post-vaccination immune responses were compared with the baseline immune response (before the first vaccine dose).
The serum samples collected from the volunteers were analyzed for IgG-specific antibodies against the spike receptor-binding domain (RBD) of SARS-CoV-2. By estimating serum antibody titers, the scientists observed that compared to the baseline values, the anti-spike RBD antibody levels increased three weeks after the first vaccine dose. The antibody levels peaked at one week after the second dose, followed by a gradual decline. Specifically, they observed a 45% reduction in antibody level between one and six weeks after the second dose. The majority of volunteers showed a similar trend of declining antibody levels. However, only 4% of volunteers exhibited increased antibody levels at six weeks after the second dose. Interestingly, they observed that the IgG-specific anti-spike RBD antibody levels in COVID 19 recovered patients were significantly lower than observed in volunteers who received the second vaccine dose.
However, volunteers immunized with only the first dose showed relatively lower antibody levels than COVID-19 recovered patients. The scientists identified age as a major contributing factor for vaccine efficacy, which showed a negative correlation with antibody response at all time points tested. The volunteers aged less than 40 years showed significantly higher antibody levels at all tested time points compared to those above 40 years. Furthermore, they observed that the negative correlation between age and vaccine-induced immune response was significantly more prominent in male volunteers than female volunteers. About 93% of volunteers reported having mild to moderate side-effects, including swelling/pain at the injection site, fatigue, malaise, headache, chills, fever, or myalgia. However, about 22% of volunteers reported having long-lasting side-effects that resulted in workplace absenteeism and impaired daily life activities.
Interestingly, some of the side-effects, including fever, headache, fatigue, malaise, chills, and nausea, showed a strong positive correlation with vaccine-related immune responses. This correlation was significantly more prominent among male volunteers than female volunteers. Regarding age variation, older volunteers showed relatively fewer adverse side-effects than younger volunteers.
- A cura del Dr. Gianfrancesco Cormaci, PhD, specialista in Biochimica Clinica.
Menni C et al. The Lancet: Infect Dis 2021 Apr 27.
Valdes AM et al. EClinicalMed. 2021 Apr 15; 34:100835.
Naaber,P et al. medRxiv 10.1101/2021.04.19.21255714v1.
Dott. Gianfrancesco Cormaci
Ultimi post di Dott. Gianfrancesco Cormaci (vedi tutti)
- I farmaci ACE-inibitori: cosa sono, come funzionano e per cosa vengono utilizzati - Ottobre 6, 2022
- Anticoagulanti ed antiaggreganti piastrinici: una rassegna di base per sapere cosa sono e come si usano - Ottobre 6, 2022
- Retinoblastoma gets “viewed” from within: and the nuclear receptor hopes for drug solution sightin’ - Ottobre 6, 2022
- Vasculopatie e tumori che condividono meccanismi comuni: sulla comprensione di chi “spiana il terreno” per chi - Ottobre 6, 2022
- Ricerche sulla predisposizione all’embolia venosa nei tumori: le correlazioni con i gruppi sanguigni - Ottobre 6, 2022